AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32943001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, or poor appetite during pregnancy
Number of subjects: 3623
Study 32943001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, or poor appetite during pregnancy (second trimester)
Number of subjects: 3623
Study 32943001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, or poor appetite during pregnancy (third trimester)
Number of subjects: 3623
Study 32943021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference measured via Brief Pain Inventory (London cohort) or Neck Disability Index (Chicago cohort)
Number of subjects: 241
Study 32943021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity measured using numeric pain rating scale
Number of subjects: 241
Study 32943047 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment at baseline
Number of subjects: 22125
Study 32943047 — intervention group
Group type: COMPARATOR
Intervention: No inhaled corticosteroids (ICS) treatment at baseline
Number of subjects: 22125
Study 32943047 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eosinophil count ≤ 150 cells/μL
Number of subjects: 22125
Study 32943047 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eosinophil count 150-300 cells/μL
Number of subjects: 22125
Study 32943047 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eosinophil count > 300 cells/μL
Number of subjects: 22125
Study 32943098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg/month for 7 infusions)
Number of subjects: 13
Study 32943156 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3488
Study 32943156 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3488
Study 32943160 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dosing of DOACs
Number of subjects: 342926
Study 32943160 — intervention group
Group type: EXPERIMENTAL
Intervention: Underdosing of DOACs
Number of subjects: 342926
Study 32943160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdosing of DOACs
Number of subjects: 342926
Study 32943160 — intervention group
Group type: COMPARATOR
Intervention: Nonrecommended dosing of DOACs (combined underdosing and overdosing)
Number of subjects: 342926
Study 32943286 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular T-cell‒mediated rejection (TCMR) scores in TBBs
Number of subjects: 457
Study 32943286 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular T-cell‒mediated rejection (TCMR) scores in mucosal biopsies
Number of subjects: 457
Study 32943286 — intervention group
Group type: COMPARATOR
Intervention: Histologic rejection
Number of subjects: 457
Study 32943286 — intervention group
Group type: COMPARATOR
Intervention: Donor-specific antibodies
Number of subjects: 457
Study 32943410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib or pirfenidone (censored from survival and progression analyses)
Number of subjects: 617
Study 32943410 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (patients not receiving antifibrotic therapy)
Number of subjects: 617
Study 32943436 — intervention group
Group type: EXPERIMENTAL
Intervention: People with IBD
Number of subjects: 0
Study 32943436 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 32943536 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 7639
Study 32943536 — intervention group
Group type: EXPERIMENTAL
Intervention: Early HRF
Number of subjects: 7639
Study 32944251 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (WBV) plus teriparatide
Number of subjects: 35
Study 32944251 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide alone
Number of subjects: 35
Study 32944253 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai version of the foot function index (FFI-Th)
Number of subjects: 49
Study 32944273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind the Gap (MTG) intervention delivered by peer coaches over 12 meetings in 18 weeks.
Number of subjects: 9
Study 32944274 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based lifestyle modification program
Number of subjects: 10
Study 32944274 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 10
Study 32944276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention
Number of subjects: 50
Study 32944276 — intervention group
Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 50
Study 32944767 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ECG recorded at hospital admission
Number of subjects: 431
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis (OA)
Number of subjects: 123
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent osteochondral lesion of talus (R-OLT)
Number of subjects: 123
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary osteochondral lesion of talus (P-OLT)
Number of subjects: 123
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral ankle instability (INST)
Number of subjects: 123
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior ankle impingement (ANT-IMP)
Number of subjects: 123
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior ankle impingement (POST-IMP)
Number of subjects: 123
Study 32944803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ankle impingement (COMB-IMP)
Number of subjects: 123
Study 32945202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (DP)
Number of subjects: 9
Study 32945596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/day for ≥ 2 weeks
Number of subjects: 22
Study 32945596 — intervention group
Group type: COMPARATOR
Intervention: Single doses of ethinylestradiol (EE) 30 μg and levonorgestrel (LN) 150 μg
Number of subjects: 22
Study 32945596 — intervention group
Group type: COMPARATOR
Intervention: Single doses of bupropion (75 mg) and midazolam (2 mg)
Number of subjects: 22
Study 32945631 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix, a novel oral gonadotropin releasing hormone receptor antagonist, indicated for management of moderate-to-severe pain associated with endometriosis
Number of subjects: 0
Study 32945728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality and duration interventions, specific details not available
Number of subjects: 0
Study 32945968 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system-based score ≥ 30
Number of subjects: 697
Study 32945968 — intervention group
Group type: EXPERIMENTAL
Intervention: RALE score ≥ 12
Number of subjects: 697
Study 32945968 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male sex, coronary artery disease, COPD, neurodegenerative disease
Number of subjects: 697
Study 32946372 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation
Number of subjects: 16
Study 32946702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device
Number of subjects: 0
Study 32946702 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32946725 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy-naive patients
Number of subjects: 1397
Study 32946850 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging (K-means clustering)
Number of subjects: 5873
Study 32946850 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema cluster
Number of subjects: 5873
Study 32946850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial epithelial gene expression
Number of subjects: 5873
Study 32946850 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial cluster
Number of subjects: 5873
Study 32947291 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 23
Study 32947291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 23
Study 32947291 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin with lactated Ringer's solution
Number of subjects: 23
Study 32947434 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 10
Study 32947651 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP14 (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days)
Number of subjects: 138
Study 32948184 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline log(calcification score)
Number of subjects: 198
Study 32948184 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 198
Study 32948184 — intervention group
Group type: EXPERIMENTAL
Intervention: log(RANKL)
Number of subjects: 198
Study 32948184 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous ischemic cardiomyopathy
Number of subjects: 198
Study 32948184 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 198
Study 32948184 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of follow up
Number of subjects: 198
Study 32948202 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (with and without COPD)
Number of subjects: 118
Study 32948202 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic bronchitis
Number of subjects: 118
Study 32948202 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 118
Study 32948202 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 118
Study 32948563 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography (POCUS)
Number of subjects: 574
Study 32948575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss and vestibular decline
Number of subjects: 100
Study 32948575 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional neuropsychological assessments
Number of subjects: 100
Study 32948575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical auditory-evoked potentials
Number of subjects: 100
Study 32948575 — intervention group
Group type: EXPERIMENTAL
Intervention: General and disease-specific health-related quality of life
Number of subjects: 100
Study 32948575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular decline
Number of subjects: 100
Study 32948953 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life conversation game played in groups of 4-6
Number of subjects: 428
Study 32948982 — intervention group
Group type: EXPERIMENTAL
Intervention: Open architecture polyetheretherketone (PEEK) interference screw
Number of subjects: 12
Study 32949123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT) for 14 weeks
Number of subjects: 33
Study 32949150 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib treatment
Number of subjects: 30
Study 32949176 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg p.o. once every day (days 1-14, with a 21-day cycle)
Number of subjects: 1
Study 32949176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temozolomide chemotherapy 100 mg/m²
Number of subjects: 1
Study 32949593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-fibrotic M2 macrophage markers
Number of subjects: 0
Study 32949828 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-biopsy after first line treatment
Number of subjects: 51
Study 32950058 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 1
Study 32950058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic islet transplantation
Number of subjects: 1
Study 32950058 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment during kidney transplantation
Number of subjects: 1
Study 32950075 — intervention group
Group type: EXPERIMENTAL
Intervention: Before lockdown (4 weeks prior)
Number of subjects: 1167
Study 32950075 — intervention group
Group type: COMPARATOR
Intervention: After lockdown (4 weeks following)
Number of subjects: 1167
Study 32950419 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel monotherapy for 3 months
Number of subjects: 201
Study 32950448 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aldosteronism (PA)
Number of subjects: 80
Study 32950448 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertension (HTN)
Number of subjects: 80
Study 32950448 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary aldosteronism due to Bartter/Gitelman (BG) syndrome
Number of subjects: 80
Study 32950448 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (HS)
Number of subjects: 80
Study 32950749 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic liver disease (CLD) patients with COVID-19
Number of subjects: 978
Study 32950785 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood maltreatment (CMT)
Number of subjects: 663
Study 32950785 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple types of childhood maltreatment (CMT)
Number of subjects: 663
Study 32950849 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 status assessment
Number of subjects: 0
Study 32950849 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32951150 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (oral doses from 10 to 80 mg)
Number of subjects: 141
Study 32951151 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320)
Number of subjects: 38
Study 32951151 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma administered early in the disease course (severe illness group)
Number of subjects: 38
Study 32951151 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 38
Study 32951470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 37
Study 32951470 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 37
Study 32951537 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 1445
Study 32951537 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1445
Study 32951537 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1445
Study 32951540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predicting morbidity
Number of subjects: 282
Study 32951540 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple symptomatic hemorrhages, initial neurological function after hemorrhage, brainstem location, and associated developmental venous anomaly
Number of subjects: 282
Study 32951684 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dose of fish oil (mean target dose 6.63 g/day to 4.06 g/day)
Number of subjects: 46
Study 32951684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic modeling of fish oil dosing
Number of subjects: 46
Study 32951684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian design for dosing algorithm
Number of subjects: 46
Study 32951957 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSinus score prediction for spontaneous conversion to sinus rhythm
Number of subjects: 2426
Study 32952616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 84
Study 32952616 — intervention group
Group type: COMPARATOR
Intervention: Control group (group III)
Number of subjects: 84
Study 32953426 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 2470
Study 32954239 — intervention group
Group type: EXPERIMENTAL
Intervention: STROKE-CARD care
Number of subjects: 2149
Study 32954239 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2149
Study 32954238 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application UnityPhilly for naloxone administration
Number of subjects: 112
Study 32954286 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham stroke-risk score
Number of subjects: 0
Study 32954622 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA (Pulmonary Endarterectomy)
Number of subjects: 593
Study 32954622 — intervention group
Group type: EXPERIMENTAL
Intervention: BPA (Balloon Pulmonary Angioplasty)
Number of subjects: 593
Study 32954622 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 593
Study 32954622 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (combined treatment)
Number of subjects: 593
Study 32954946 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking intervention in a visual search paradigm
Number of subjects: 0
Study 32954946 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) intervention
Number of subjects: 0
Study 32955038 — intervention group
Group type: EXPERIMENTAL
Intervention: CADOT index
Number of subjects: 699
Study 32955038 — intervention group
Group type: COMPARATOR
Intervention: BODE index
Number of subjects: 699
Study 32955038 — intervention group
Group type: COMPARATOR
Intervention: ADO index
Number of subjects: 699
Study 32955159 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia crowns
Number of subjects: 30
Study 32955159 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic crowns
Number of subjects: 30
Study 32955159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scanning
Number of subjects: 30
Study 32955159 — intervention group
Group type: COMPARATOR
Intervention: Control enamel
Number of subjects: 30
Study 32955176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 129
Study 32955197 — intervention group
Group type: EXPERIMENTAL
Intervention: First course of fecal microbiota transplantation (FMT)
Number of subjects: 202
Study 32955197 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of fecal microbiota transplantation (FMT)
Number of subjects: 202
Study 32955197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 202
Study 32955198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 2083
Study 32955198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose ingestion
Number of subjects: 2083
Study 32955198 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized extra-GI symptoms
Number of subjects: 2083
Study 32955198 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen and methane breath concentrations
Number of subjects: 2083
Study 32955488 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4 haploinsufficiency (CTLA4h)
Number of subjects: 50
Study 32955714 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus patient-tailored adherence interventions
Number of subjects: 438
Study 32955714 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 438
Study 32956379 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB)
Number of subjects: 124
Study 32956379 — intervention group
Group type: COMPARATOR
Intervention: Conventional transbronchial lung biopsy (TBLB)
Number of subjects: 124
Study 32956380 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently low CD4 counts (21%)
Number of subjects: 688
Study 32956380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4 counts that increased over time (22%)
Number of subjects: 688
Study 32956380 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CD4 counts that remained stable (41%)
Number of subjects: 688
Study 32956380 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD4 counts that increased over time (16%)
Number of subjects: 688
Study 32956380 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation within 3 months of diagnosis
Number of subjects: 688
Study 32956407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 or 6.0 mg/kg/day
Number of subjects: 23
Study 32956453 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab (JNJ-64007957)
Number of subjects: 0
Study 32956453 — intervention group
Group type: COMPARATOR
Intervention: Vehicle and antibody controls
Number of subjects: 0
Study 32956536 — intervention group
Group type: COMPARATOR
Intervention: Magnesium supplementation
Number of subjects: 735
Study 32956651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 23
Study 32956688 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal targeted biopsy (TP-TBx)
Number of subjects: 379
Study 32956688 — intervention group
Group type: COMPARATOR
Intervention: Transrectal targeted biopsy (TR-TBx)
Number of subjects: 379
Study 32957363 — intervention group
Group type: EXPERIMENTAL
Intervention: SH003 combined with docetaxel
Number of subjects: 6
Study 32957921 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional home services
Number of subjects: 1168
Study 32957921 — intervention group
Group type: COMPARATOR
Intervention: No professional home services
Number of subjects: 1168
Study 32957944 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT for Health in Adolescents (AHEAD)
Number of subjects: 21
Study 32958031 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabby Preconception Care System (PCC) intervention
Number of subjects: 600
Study 32958357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging (mpMRI) screening
Number of subjects: 188
Study 32958357 — intervention group
Group type: COMPARATOR
Intervention: Age-stratified PSA screening
Number of subjects: 188
Study 32958357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy after elevated PSA or suspicious mpMRI
Number of subjects: 188
Study 32958357 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis for screening strategies
Number of subjects: 188
Study 32958357 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PCa risk between BRCA1 and BRCA2
Number of subjects: 188
Study 32958438 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-mediated renal sympathetic neurolysis using the Peregrine Catheter
Number of subjects: 0
Study 32958438 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 32958451 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Number of subjects: 168
Study 32958451 — intervention group
Group type: COMPARATOR
Intervention: CI
Number of subjects: 168